Momenta Pharmaceuticals Form 4 / YOUNG KWON ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KWON YOUNG

(Last)

(First)

(Middle)

C/O MOMENTA PHARMACEUTICALS, INC.

301 BINNEY STREET

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MOMENTA PHARMACEUTICALS INC [ MNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial & Bus. Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2020		D		160,633	D	⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽²⁾	10/01/2020		D			45,000	⁽²⁾	⁽²⁾	Common Stock	45,000	⁽²⁾	0	D
Restricted Stock Units	⁽²⁾	10/01/2020		D			2,819	⁽²⁾	⁽²⁾	Common Stock	2,819	⁽²⁾	0	D
Restricted Stock Unit	⁽²⁾	10/01/2020		D			31,500	⁽²⁾	⁽²⁾	Common Stock	31,500	⁽²⁾	0	D
Restricted Stock Units	⁽²⁾	10/01/2020		D			50,000	⁽²⁾	⁽²⁾	Common Stock	50,000	⁽²⁾	0	D
Stock Option (Right to Buy)	$12.58	10/01/2020		D			3,572	⁽³⁾	02/19/2023	Common Stock	3,572	⁽³⁾	0	D
Stock Option (Right to Buy)	$17.96	10/01/2020		D			3,466	⁽³⁾	02/18/2024	Common Stock	3,466	⁽³⁾	0	D
Stock Option (Right to Buy)	$13.02	10/01/2020		D			6,712	⁽³⁾	02/18/2025	Common Stock	6,712	⁽³⁾	0	D
Stock Option (Right to Buy)	$21.56	10/01/2020		D			3,214	⁽³⁾	08/11/2025	Common Stock	3,214	⁽³⁾	0	D
Stock Option (Right to Buy)	$10.83	10/01/2020		D			2,363	⁽³⁾	02/09/2026	Common Stock	2,363	⁽³⁾	0	D
Stock Option (Right to Buy)	$18.85	10/01/2020		D			6,766	⁽³⁾	02/07/2027	Common Stock	6,766	⁽³⁾	0	D
Stock Option (Right to Buy)	$12.76	10/01/2020		D			19,344	⁽³⁾	02/11/2029	Common Stock	19,344	⁽³⁾	0	D
Stock Option (Right to Buy)	$31.87	10/01/2020		D			3,137	⁽³⁾	02/07/2030	Common Stock	3,137	⁽³⁾	0	D
Stock Option (Right to Buy)	$13.26	10/01/2020		D			8,502	⁽³⁾	02/22/2021	Common Stock	8,502	⁽³⁾	0	D
Stock Option (Right to Buy)	$12.58	10/01/2020		D			7,228	⁽³⁾	02/19/2023	Common Stock	7,228	⁽³⁾	0	D
Stock Option (Right to Buy)	$17.96	10/01/2020		D			1,356	⁽³⁾	02/18/2024	Common Stock	1,356	⁽³⁾	0	D
Stock Option (Right to Buy)	$13.02	10/01/2020		D			13,013	⁽³⁾	02/18/2025	Common Stock	13,013	⁽³⁾	0	D
Stock Option (Right to Buy)	$21.56	10/01/2020		D			6,786	⁽³⁾	08/11/2025	Common Stock	6,786	⁽³⁾	0	D
Stock Option (Right to Buy)	$10.83	10/01/2020		D			35,437	⁽³⁾	02/09/2026	Common Stock	35,437	⁽³⁾	0	D
Stock Option (Right to Buy)	$18.85	10/01/2020		D			38,334	⁽³⁾	02/07/2027	Common Stock	38,334	⁽³⁾	0	D
Stock Option (Right to Buy)	$12.76	10/01/2020		D			115,656	⁽³⁾	02/11/2029	Common Stock	115,656	⁽³⁾	0	D
Stock Option (Right to Buy)	$31.87	10/01/2020		D			96,863	⁽³⁾	02/07/2030	Common Stock	96,863	⁽³⁾	0	D

Explanation of Responses:

1. Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

2. Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.

3. Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

	/s/ R. Mark Chamberlin as attorney in fact	10/01/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Momenta Pharmaceuticals (MNTA) Form 4MOMENTA PHARMACEUTICALS / YOUNG KWON ownership change